Multispan recognized the need for improved β-Arrestin screening assays and developed a novel HTS technology, MULTISCREEN™ β-Arrestin Sensor technology, that can assess β-Arrestin signaling of native GPCRs in recombinant or primary cells – a critical aspect for assessing receptor physiology.
Our assay kits, reagents and services based on MULTISCREEN™ β-Arrestin sensor technology enable researchers to examine unmodified GPCRs, including endogenously expressed GPCR targets, which provide more relevant data for
improved identification and optimization of qualified drug candidates.